Clinical Evaluation of Early Post-Marketing Phase Vigilance-Features of Adverse Events Noted in Early Post-marketing Phase Vigilance

MLA

Daisuke Tani, et al. “Clinical Evaluation of Early Post-Marketing Phase Vigilance-Features of Adverse Events Noted in Early Post-Marketing Phase Vigilance.” Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), vol. 31, Jan. 2005, pp. 632–37. EBSCOhost, https://doi.org/10.5649/jjphcs.31.632.

APA

Daisuke Tani, Ryoichi Yano, Yuichiro Kayano, Sadaaki Maeda, Hitoshi Tsukamoto, Kyohei Watanabe, Yoshifumi Wakiya, Hironao Aono, Masaki Shirahase, Nobuyuki Goto, & Mikio Masada. (2005). Clinical Evaluation of Early Post-Marketing Phase Vigilance-Features of Adverse Events Noted in Early Post-marketing Phase Vigilance. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 31, 632–637. https://doi.org/10.5649/jjphcs.31.632

Chicago

Daisuke Tani, Ryoichi Yano, Yuichiro Kayano, Sadaaki Maeda, Hitoshi Tsukamoto, Kyohei Watanabe, Yoshifumi Wakiya, et al. 2005. “Clinical Evaluation of Early Post-Marketing Phase Vigilance-Features of Adverse Events Noted in Early Post-Marketing Phase Vigilance.” Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 31 (January): 632–37. doi:10.5649/jjphcs.31.632.